JP2023538419A5 - - Google Patents

Info

Publication number
JP2023538419A5
JP2023538419A5 JP2023512647A JP2023512647A JP2023538419A5 JP 2023538419 A5 JP2023538419 A5 JP 2023538419A5 JP 2023512647 A JP2023512647 A JP 2023512647A JP 2023512647 A JP2023512647 A JP 2023512647A JP 2023538419 A5 JP2023538419 A5 JP 2023538419A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
composition according
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023512647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538419A (ja
JP7794807B2 (ja
Filing date
Publication date
Priority claimed from EP20382764.7A external-priority patent/EP3957308A1/en
Application filed filed Critical
Publication of JP2023538419A publication Critical patent/JP2023538419A/ja
Publication of JP2023538419A5 publication Critical patent/JP2023538419A5/ja
Application granted granted Critical
Publication of JP7794807B2 publication Critical patent/JP7794807B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023512647A 2020-08-21 2021-08-20 気道疾患の治療に使用するための(1r,3s)-3-((5-シアノ-4-フェニルチアゾール-2-イル)カルバモイル)シクロペンタン-1-カルボン酸およびその誘導体 Active JP7794807B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382764.7A EP3957308A1 (en) 2020-08-21 2020-08-21 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
EP20382764.7 2020-08-21
PCT/EP2021/073133 WO2022038261A1 (en) 2020-08-21 2021-08-20 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases

Publications (3)

Publication Number Publication Date
JP2023538419A JP2023538419A (ja) 2023-09-07
JP2023538419A5 true JP2023538419A5 (cg-RX-API-DMAC7.html) 2024-07-29
JP7794807B2 JP7794807B2 (ja) 2026-01-06

Family

ID=72234795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512647A Active JP7794807B2 (ja) 2020-08-21 2021-08-20 気道疾患の治療に使用するための(1r,3s)-3-((5-シアノ-4-フェニルチアゾール-2-イル)カルバモイル)シクロペンタン-1-カルボン酸およびその誘導体

Country Status (20)

Country Link
US (1) US20230321053A1 (cg-RX-API-DMAC7.html)
EP (2) EP3957308A1 (cg-RX-API-DMAC7.html)
JP (1) JP7794807B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230054444A (cg-RX-API-DMAC7.html)
CN (1) CN115942933A (cg-RX-API-DMAC7.html)
AU (1) AU2021327728B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023002778A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190081A1 (cg-RX-API-DMAC7.html)
DK (1) DK4199922T3 (cg-RX-API-DMAC7.html)
ES (1) ES3001104T3 (cg-RX-API-DMAC7.html)
FI (1) FI4199922T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241621T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069338T2 (cg-RX-API-DMAC7.html)
LT (1) LT4199922T (cg-RX-API-DMAC7.html)
MX (1) MX2023002156A (cg-RX-API-DMAC7.html)
PL (1) PL4199922T3 (cg-RX-API-DMAC7.html)
PT (1) PT4199922T (cg-RX-API-DMAC7.html)
RS (1) RS66263B1 (cg-RX-API-DMAC7.html)
SI (1) SI4199922T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022038261A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001881A2 (en) * 2006-03-07 2008-12-17 Endacea, Inc. Compositions and methods for treating respiratory disorders
ES2331220B1 (es) 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
AU2015315628A1 (en) * 2014-09-08 2017-04-20 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
LT3592734T (lt) 2017-03-06 2021-07-26 Palobiofarma, S.L. (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska

Similar Documents

Publication Publication Date Title
JP5492072B2 (ja) 喘息の増悪の予防および/または治療のためのフォルモテロールおよびジプロピオン酸ベクロメタゾンを含む組成物の使用
AU2020226339B2 (en) Methods of treatment of respiratory disorders
CN106488770A (zh) 用于治疗copd的福莫特罗和布地奈德的组合
FI4199922T3 (fi) (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa
JP5068912B2 (ja) ロテプレドノールとβ2アドレナリン受容体アゴニストの新規組み合わせ
US20190224164A1 (en) Compositions and methods for treatment of copd
US20020198228A1 (en) Composition and method for the treatment of respiratory desease
JP6021952B2 (ja) 慢性閉塞性肺疾患の治療法
JP6188784B2 (ja) 炎症性および免疫性疾患の治療のための組成物
JP2016504358A (ja) オキシブチニンを投与するための方法および組成物
US10959992B2 (en) Methods of treatment of asthma and COPD
WO2026052051A1 (zh) 杂环化合物在治疗肺疾病中的应用
NZ707754B2 (en) Combination of glycopyrrolate and a beta2 -agonist